A comprehensive view of Janssen Pharmaceutical Companies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Janssen Pharmaceutical Companies Amplifies Patient Voices on #WorldPHDay2024, Highlighting Industry Progress and Community Support in Pulmonary Hypertension
Published: May 06, 2024 by Industry Intelligence Inc.
TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non–muscle-invasive bladder cancer, respectively
Published: May 05, 2024 by Janssen Pharmaceutical Companies
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non–muscle-invasive bladder cancer
Published: May 03, 2024 by Janssen Pharmaceutical Companies
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery
Published: May 03, 2024 by Janssen Pharmaceutical Companies
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA® (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease
Published: May 01, 2024 by Janssen Pharmaceutical Companies

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count